ACADIA Pharmaceuticals (NASDAQ:ACAD) PT Lowered to $28.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price cut by investment analysts at Morgan Stanley from $30.00 to $28.00 in a report issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential upside of 57.84% from the company’s current price.

ACAD has been the subject of several other research reports. Oppenheimer restated a “market perform” rating and issued a $19.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, May 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $29.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, June 25th. Robert W. Baird reduced their price target on ACADIA Pharmaceuticals from $31.00 to $28.00 and set an “outperform” rating for the company in a report on Thursday, May 9th. Mizuho reduced their price target on ACADIA Pharmaceuticals from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Thursday, May 9th. Finally, JPMorgan Chase & Co. reduced their price target on ACADIA Pharmaceuticals from $29.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, March 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.59.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD traded up $0.09 during midday trading on Friday, hitting $17.74. The stock had a trading volume of 700,451 shares, compared to its average volume of 1,724,612. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -1,772.23 and a beta of 0.38. The company has a 50 day simple moving average of $15.58 and a two-hundred day simple moving average of $20.60. ACADIA Pharmaceuticals has a twelve month low of $14.55 and a twelve month high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.06. The company had revenue of $205.83 million during the quarter, compared to analysts’ expectations of $208.31 million. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. ACADIA Pharmaceuticals’s revenue for the quarter was up 73.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.27) EPS. Analysts forecast that ACADIA Pharmaceuticals will post 0.58 EPS for the current fiscal year.

Insider Activity

In other news, CEO Stephen Davis sold 11,427 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total value of $193,573.38. Following the completion of the sale, the chief executive officer now directly owns 155,231 shares in the company, valued at $2,629,613.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 3,503 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $59,340.82. Following the sale, the chief financial officer now owns 32,053 shares of the company’s stock, valued at $542,977.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephen Davis sold 11,427 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $16.94, for a total transaction of $193,573.38. Following the sale, the chief executive officer now directly owns 155,231 shares in the company, valued at approximately $2,629,613.14. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,708 shares of company stock worth $348,697. Corporate insiders own 28.30% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Empire Life Investments Inc. grew its stake in shares of ACADIA Pharmaceuticals by 0.3% during the fourth quarter. Empire Life Investments Inc. now owns 174,815 shares of the biopharmaceutical company’s stock worth $5,473,000 after buying an additional 467 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of ACADIA Pharmaceuticals by 2.3% in the fourth quarter. Handelsbanken Fonder AB now owns 31,633 shares of the biopharmaceutical company’s stock worth $990,000 after purchasing an additional 700 shares during the last quarter. Swiss National Bank grew its stake in shares of ACADIA Pharmaceuticals by 0.4% in the first quarter. Swiss National Bank now owns 210,604 shares of the biopharmaceutical company’s stock worth $3,894,000 after purchasing an additional 800 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of ACADIA Pharmaceuticals by 1.6% in the fourth quarter. Franklin Resources Inc. now owns 50,405 shares of the biopharmaceutical company’s stock worth $1,578,000 after purchasing an additional 803 shares during the last quarter. Finally, Covestor Ltd grew its stake in shares of ACADIA Pharmaceuticals by 70.5% in the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 840 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.